Literature DB >> 25054033

Health resource utilisation associated with skeletal-related events in European patients with lung cancer: Α subgroup analysis from a prospective multinational study.

Vito Lorusso1, Ignacio Duran2, Cristina Garzon-Rodriguez3, Diana Lüftner4, Amit Bahl5, John Ashcroft6, Guy Hechmati7, Rachel Wei8, Emma Thomas9, Herbert Hoefeler10.   

Abstract

Bone complications or skeletal-related events (SREs), typically defined as radiation to bone, pathological fractures, surgery to bone and spinal cord compression, occur frequently in patients with bone metastases. As the survival of patients with advanced lung cancer improves, preventing SREs is becoming increasingly clinically relevant. The aim of this analysis was to assess the impact of SREs on health resource utilisation (HRU) in European lung cancer patients with bone metastasis. This multinational, observational study included patients who had at least one SRE in the 97 days prior to enrolment, a life expectancy of ≥6 months and an Eastern Cooperative Oncology Group performance status of 0-2. Data on HRU were retrospectively collected for up to 97 days prior to enrolment with a planned prospective follow-up for up to 18-21 months. The HRU measures included the number and length of inpatient hospitalisations and the number of outpatient visits and procedures. The investigators determined whether each HRU was attributable to a SRE. In total, 135 patients with lung cancer, enrolled at centres in Germany, Italy, Spain and the United Kingdom, contributed 214 SREs to this analysis. The median length [quartile (Q)1, Q3] of follow-up ranged from 1.5 (0.7, 3.3) to 5.6 (2.0, 8.2) months across the countries. Overall, 41% of the SREs required an inpatient stay, with a median (Q1, Q3) duration of 19.0 (6.0, 28.0) days. Spinal cord compression and surgery to bone were the SRE types most frequently requiring inpatient stays. Radiation to bone was associated with the largest number of outpatient visits and procedures. All the SREs resulting from bone metastases in patients with lung cancer contribute considerably to HRU and efforts to minimise the incidence of bone complications in these patients through appropriate treatments may help reduce this burden.

Entities:  

Keywords:  Europe; bone metastases; disease burden; healthcare resource utilisation; lung cancer; skeletal-related events

Year:  2014        PMID: 25054033      PMCID: PMC4106737          DOI: 10.3892/mco.2014.330

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  20 in total

1.  Radiotherapy dose fractionation, access and waiting times in the countries of the UK in 2005.

Authors:  M V Williams; E T Summers; K Drinkwater; A Barrett
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-06       Impact factor: 4.126

2.  The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.

Authors:  Thomas Delea; Corey Langer; James McKiernan; Martin Liss; John Edelsberg; Jane Brandman; Jennifer Sung; Monika Raut; Gerry Oster
Journal:  Oncology       Date:  2004       Impact factor: 2.935

Review 3.  Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group.

Authors:  D Andrew Loblaw; James Perry; Alexandra Chambers; Normand J Laperriere
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

4.  Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease--a short communication.

Authors:  R Calderone; K Nimako; A Leary; S Popat; M E R O'Brien
Journal:  Eur J Cancer       Date:  2011-06-16       Impact factor: 9.162

5.  The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium.

Authors:  Jean-Jacques Body; Pierre Chevalier; Oliver Gunther; Guy Hechmati; Mark Lamotte
Journal:  J Med Econ       Date:  2013-02-21       Impact factor: 2.448

6.  Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study.

Authors:  G Hechmati; S Cure; A Gouépo; H Hoefeler; V Lorusso; D Lüftner; I Duran; C Garzon-Rodriguez; J Ashcroft; R Wei; P Ghelani; A Bahl
Journal:  J Med Econ       Date:  2013-03-15       Impact factor: 2.448

7.  Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.

Authors:  Lee S Rosen; David Gordon; N Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; Maciej Krzakowski; Marek Pawlicki; Paul De Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John Seaman
Journal:  Cancer       Date:  2004-06-15       Impact factor: 6.860

8.  Economic burden of metastatic bone disease in the U.S.

Authors:  Kathy L Schulman; Joseph Kohles
Journal:  Cancer       Date:  2007-06-01       Impact factor: 6.860

Review 9.  Skeletal complications of malignancy.

Authors:  R E Coleman
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

Review 10.  Impact of skeletal complications on patients' quality of life, mobility, and functional independence.

Authors:  Luis Costa; Xavier Badia; Edward Chow; Allan Lipton; Andrew Wardley
Journal:  Support Care Cancer       Date:  2008-04-08       Impact factor: 3.359

View more
  3 in total

1.  Combination of icotinib, surgery, and internal-radiotherapy of a patient with lung cancer severely metastasized to the vertebrae bones with EGFR mutation: a case report.

Authors:  Li-Li Qu; Hai-Feng Qin; Hong-Jun Gao; Xiao-Qing Liu
Journal:  Onco Targets Ther       Date:  2015-06-02       Impact factor: 4.147

2.  Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study.

Authors:  Dae Ho Lee; Hiroshi Isobe; Hubert Wirtz; Sabina Bandeira Aleixo; Phillip Parente; Filippo de Marinis; Min Huang; Ashwini Arunachalam; Smita Kothari; Xiting Cao; Nello Donnini; Ann-Marie Woodgate; Javier de Castro
Journal:  BMC Health Serv Res       Date:  2018-03-01       Impact factor: 2.655

3.  The Impact of Lung Carcinoma Histology on the Frequency of Bone Metastases.

Authors:  Marcelo Bragança Dos Reis Oliveira; Larissa Costa Souza; Ermides Javier Garcia Sampayo; Gustavo Sobral de Carvalho; Fernanda Carvalho de Queiroz Mello; Marcos Eduardo Machado Paschoal
Journal:  Rev Bras Ortop (Sao Paulo)       Date:  2019-09-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.